Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nichi-Iko Buys Sagent To Strengthen US Biosimilars Presence

Executive Summary

Nichi-Iko Pharmaceutical Co. Ltd. will pay $736m in cash for Sagent Pharmaceuticals Inc. in a deal that will further expand the Japanese company's biosimilars business beyond Asia and diversify the US generics firm's injectable medicines portfolio.

Advertisement

Related Content

Aprogen/Nichi-Iko's Remicade Biosimilar Clears Japan’s Approval Review
Aprogen/Nichi-Iko's Remicade Biosimilar Clears Japan’s Approval Review
Asia On The Move: Nichi-Iko Names Outsider To Lead Sagent
Teva Continues Divestitures To Close Allergan Deal With Sale To Impax
Data Take: Forget Teva and Mylan - Big Pharma Owns Generics
Aprogen Strikes Third Global Biosimilar Deal With Nichi-Iko
BioNotebook: Two key fires at Retrophin, NewLink; three deals and three financings
Sagent Turns Generic Injectable Shortages Into Business Opportunity
Japan's Nichi-Iko prepping for US biosimilar entry
Nichi-Iko rights offering to support production, biosimilar plans

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC096870

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel